|
|
|
| An evaluation on immunization effect and the influencing factors after revaccination with 60 μg hepatitis B vaccine among non-response adults |
| CHEN Sheng -yu,YU Yun-xian,WANG Xue-cai,DONG Xiao -lian, TANG Zhi-feng,CHEN Ying-feng,WANG Xiao-li，
|
| Zhejiang University School of Public Health,Hangzhou,Zhejiang, 310058, China |
|
|
|
|
Abstract Objective To explore vaccine immune effects of 60 μg hepatitis B on adults who have no response to hepatitis B vaccination.Methods A Total of 689 healthy adults who were HBsAg and anti- HBs negative were selected,and they were received 3 doses of hepatitis B vaccine at dosage 10 μg. Those with anti- HBs＜10 IU/L detected after full series vaccination were given 1 dose of hepatitis B vaccine at dosage 60 μg.One month later,anti- HBs detection was conducted for them.Results The non -responsiveness rate was 17.71% after primary hepatitis B vaccination. The multivariate logistic regression analysis showed that risk factors for primary non-responsiveness were the history of surgical operation, immunization schedule and "anti-HBc alone". The anti- HBs positive rate was 95.51% in 89 re-vaccinated people,and the geometric mean titers of anti-HBs(GMT) was 585.39 IU/L.Conclusion Re-immunization of hepatitis B vaccine at dosage 60 μg has good immunogenicity in people who have no response to primary vaccination, and weight control may improve the effect of hepatitis B re-immunization.
|
|
Published: 26 December 2017
|
|
|
|
|
|
[1]NACHEGA J B, CHAISSON R E. Tuberculosis drug resistance: a global threat [J]. Clin Infect Dis, 2003, 36(Suppl 1):S24- 30.
[2]World Health Organization. Anti-tuberculosis drug resistance in the world. Report No. 3: The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance, 1999—2002[R]Geneva: WHO, 2004.
[3]陈松华,王晓萌,柳正卫,等.浙江省耐多药结核病例中二线耐药状况分析[J].中国预防医学杂志. 2011,12(8):221-224.
[4]中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007—2008年)[M].北京:人民卫生出版社,2010: 45.
[5]中国防痨协会基础专业委员会.结核病诊断实验室检验规程[M].北京:中国教育文化出版社,2006:47.
[6]World Health Organization.Guidelines for drug-susceptibility testing for second-line antituberculosis drugs for DOTS-plus[M].Geneva:WHO,2001:7.
[7]World Health Organization. Anti-tuberculosis drug resistance in the world. Report No. 2: Prevalence and trends. The WHO/IUATLD Global Project on Anti-tuberculosis Drug resistance Surveillance[R]. Geneva: 2000.
[8]梅建,沈鑫,沈梅,等.上海市结核分枝杆菌耐药性监测研究报告[J].中国防痨杂志,2007,29(5):395-397.
[9]徐东芳,王庆,李孳,等.安徽省420株结核分枝杆菌对一线和二线抗结核药物药敏结果分析[J].中国人兽共患病学报,2014,30(1):54-57.
[10]王晓萌,李群,韩永兴,等.浙江省肺结核病人耐药特征[J].中国防痨杂志,2000,22(3):137-138.
[11]缪梓萍,李群,何海波,等.浙江省耐药结核病现状及趋势研究[J].中国防痨杂志,2007,29(3):215-218.
[12]World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis [M].Geneva:WHO,2011:WHO/HTM/TB/2006,361.
[13]张国龙,杜长梅,苍泽卓也,等.中日合作对河南省结核菌二线药物耐药监测研究[J].医药论坛杂志,2005,26(19):14-16.
[14]WALWAIKAR P P,MORYE V K,GAWDE A S.Ofloxacin in multidrug resistant tuberculosis [J].Indian Med Assoc,2003,101(3):210-212. |
|
|
|
